- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04437420
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90 (HSP-HEMATO)
June 19, 2020 updated by: Centre Hospitalier Universitaire Dijon
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies.
While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL).
The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
44
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: François GIRODON
- Phone Number: +33 0380295710
- Email: francois.girodon@chu-dijon.fr
Study Locations
-
-
-
Dijon, France, 21000
- Recruiting
- CHU Dijon Bourgogne
-
Contact:
- Shaliha Bechoua
- Email: shaliha.bechoua@chu-dijon.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patient with acute lymphoblastic leukemia with biological samples stored at the Biology Technical Platform.
Description
Inclusion Criteria:
- Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
Exclusion Criteria:
- Patient over 80 years of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
T-ALL
|
injection of BEP 800
no injection of BEP 800
|
B-ALL
|
injection of BEP 800
no injection of BEP 800
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viability on primary ALL samples
Time Frame: 2 years
|
The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect on SRC phosphorylation
Time Frame: 2 years
|
The effect of BEP-800 on T-ALL and B-ALL will be evaluated by flow cytometry by measuring HSP90 and SRC (phosphorylated), by intracellular labeling after permeabilization of the cells, 18 hours after treatment with BEP-800.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2019
Primary Completion (Anticipated)
September 1, 2021
Study Completion (Anticipated)
September 1, 2021
Study Registration Dates
First Submitted
June 16, 2020
First Submitted That Met QC Criteria
June 17, 2020
First Posted (Actual)
June 18, 2020
Study Record Updates
Last Update Posted (Actual)
June 23, 2020
Last Update Submitted That Met QC Criteria
June 19, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIRODON Collection 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute T Lymphoblastic Leukemia (T-ALL)
-
Fundamenta Therapeutics, Ltd.The First Affiliated Hospital of University of Science and Technology of...RecruitingT-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingT-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | Early T Acute Lymphoblastic Leukemia | Etp AllItaly
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingRefractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic LeukemiaUnited States
-
The First Affiliated Hospital of Soochow UniversityThe First Affiliated Hospital of Anhui Medical University; Henan Cancer Hospital and other collaboratorsRecruitingInduction Chemotherapy | Acute T-Lymphocytic Leukemia | T-cell Lymphoblastic Lymphoma Leukemia | T-cell/Myeloid Mixed Phenotype Acute LeukemiaChina
-
Therapeutic Advances in Childhood Leukemia ConsortiumGlaxoSmithKline; NovartisTerminatedRelapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic LymphomaUnited States, France, Canada, Australia, Austria, Italy, Netherlands
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Leukemia...TerminatedT-Acute Lymphoblastic Leukemia | Adult T Lymphoblastic LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingT Acute Lymphoblastic Leukemia | T Lymphoblastic LymphomaUnited States, Canada, Australia, New Zealand, Switzerland
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Ehab L AtallahRecruitingAcute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on injection of BEP 800
-
Eisai Co., Ltd.CompletedBreast Cancer | Breast Tumors | Triple Negative Breast Cancer | Cancer of Breast | HER2-Negative Breast CancerChina
-
C. R. BardCompletedParoxysmal Atrial FibrillationCanada, Germany, United Kingdom
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; BRAC James P Grant School of Public Health...RecruitingPregnancy Complications | Preterm Birth | Low Birth Weight | Fetal Growth Retardation | Stunting | Gestational Weight Gain | Anemia of PregnancyBangladesh
-
St. Olavs HospitalKarolinska Institutet; Oslo University Hospital; University Hospital of North... and other collaboratorsRecruitingTesticular Neoplasms | SeminomaNorway
-
Cytori TherapeuticsCompletedMyocardial Infarction | Coronary Disease | Cardiovascular Disease | Coronary ArteriosclerosisSpain, Netherlands
-
Aalborg UniversityUnknown
-
Ampio Pharmaceuticals. Inc.Completed
-
SanofiCompleted
-
Benazir Bhutto Hospital, RawalpindiCombined Military Hospital, PakistanCompletedPostoperative Pain | Intravenous Drug Usage | Knee Arthroscopy | Ibuprofen | KetorolacPakistan
-
Medstar Health Research InstituteRecruitingVaginal Atrophy | Postmenopausal Symptoms | Genitourinary Syndrome of Menopause | Sexual Function Disturbances | PRPUnited States